Entities / Company
Oragenics (United States).
company in Tampa, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 22
What's happening
Gone quiet
No new reports in 90+ days-
Shuttle Pharmaceuticals must file registration statements with the Securities and Exchange Commission (Bangladesh) by June 25, 2025.Speculative5 reports
-
Oragenics seeks FDA approval for a concussion treatment, having also secured HREC approval in Australia.Some support1 report2 developments inside
-
Oragenics secures a GMP production agreement with Sterling Pharma Solutions for its concussion drug candidate, ONP-002.Some support1 report
-
Oragenics (Q30291067) is conducting its clinical trials for a concussion treatment, utilizing Southern Star Research as the CRO and David Lloyd as the programme manager.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Oragenics (United States) this week
News at the entities that move Oragenics (United States) most-
UWM Holdings Corp filed an 8-K with the Securities and Exchange Commission (Bangladesh) on May 13, 2026.
Moves Oragenics (United States)
-
Boston Shared contextThe Federal Aviation Administration is managing air traffic operations at Boston Logan Airport.Moves Oragenics (United States)
Connections
The 3 strongest of 22, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
James M. Kelly Structural
James M. Kelly serves as the Chief Medical Officer of Oragenics.
-
Oragenics is subject to formal regulatory oversight and filing requirements by the Securities and Exchange Commission of Bangladesh.
-
Boston Shared context
Oragenics operates in Boston, participating in industry summits and conventions.
History
Events by the month they beganJune 2026
4 events- Shuttle Pharmaceuticals must file registration statements with the Securities and Exchange Commission (Bangladesh) by June 25, 2025.
- Oragenics seeks FDA approval for a concussion treatment, having also secured HREC approval in Australia.
- Oragenics secures a GMP production agreement with Sterling Pharma Solutions for its concussion drug candidate, ONP-002.
- Oragenics (Q30291067) is conducting its clinical trials for a concussion treatment, utilizing Southern Star Research as the CRO and David Lloyd as the programme manager.